<DOC>
	<DOCNO>NCT01215747</DOCNO>
	<brief_summary>The primary purpose study assess efficacy safety treatment Kiacta adult patient AA Amyloidosis .</brief_summary>
	<brief_title>Efficacy Safety Study KIACTA Preventing Renal Function Decline AA Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>female must nonchildbearing potential ( 1 yr postmenopausal ) use effective contraception least 2 month prior baseline visit 30 day last dose study medication confirm diagnosis AA amyloidosis demonstrate positive biopsy use congo red stain immunohistochemistry immunoelectronmicroscopy . Mass spectroscopy use upon approval sponsor case case basis . persistent proteinuria great 1 g/24h 2 distinct 24hr urine collection must CrCl great 25 ml/min/1.73 m2 2 distinct 24 hr urine collection evidence suspicion chronic kidney disease secondary disease AA amyloidosis ( eg , diabetes , longstanding uncontrolled hypertension , polycystic kidney disease , recur polynephritis , systemic lupus erythematosus ) history kidney transplantation evidence suspicion cause potentially reversible acute renal failure within 3 month prior baseline visit presence concomitant diseases medication could interfere interpretation study result compromise patient safety presence condition could reduce life expectancy le 2 yr Type 1 2 diabetes mellitus significant hepatic enzyme elevation unstable angina , myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty within 6 month prior baseline visit ; presence NY Heart Assoc class III IV heart failure presence , history stroke transient ischemic attack within 6 month prior baseline visit initiation , change , angiotensin convert enzyme inhibitor , angiotensin II receptor antagonist therapy , renin inhibitor within 3 month prior baseline visit initiation , change , cytotoxic agent , antitumor necrosis factor agent , anti interleukin1 6 agent , colchicine therapy within 3 month prior baseline visit previous use Kiacta history malignancy within 5 yr prior study entry , except cervical carcinoma situ , nonmelanomatous carcinoma skin , ductal carcinoma situ breast surgically cure use investigational drug within 30 day prior first screen visit active alcohol and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Kiacta AA amyloidosis</keyword>
</DOC>